Cat. No.: DAA-001156
Product Information | |
---|---|
Product Name | Human IL-1β ELISA Kit |
Species | Human |
Description | Human IL-1β (Interleukin 1β) ELISA kit is a single-wash sandwich ELISA designed for the quantitative measurement of IL-1β protein in human serum, plasma, and cell culture supernatants. It uses our proprietary ELISA technology. Quantitate human IL-1β with 5.64 pg/mL sensitivity ELISA technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our ELISA plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. |
Sample Types | Cell Culture Supernatant, Serum, Hep Plasma, Edta Plasma, Cit Plasma |
Detection Range | 14.06 pg/mL - 900 pg/mL |
Sensitivity | 5.64 pg/mL |
Target Information | |
---|---|
Target Name | IL1B |
UniProt No. | P01584 |
Gene ID | 3553 |
Target Description | Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. |
Alternative Names | Catabolin; H1; IFNβ inducing factor; IL 1; IL 1β; IL-1β; IL1; IL1β; IL1B; IL1B_HUMAN; IL1F2; Interleukin 1β; Interleukin 1β precursor; interleukin 1, β; Interleukin-1β; OAF; Osteoclast activating factor; OTTHUMP00000162031; Preinterleukin 1β; Preinterleukinβ; Pro interleukin 1β |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.